Abstract: Content providers may wish to display different versions of content to different users, which may require different versions of the content to be deliverable. The assignment of a particular version of the content to a particular user may also need to persist over time for that particular user. It may be desirable that this functionality occurs at an edge server of a content delivery network, rather than at an origin server. In some embodiments, the edge server may receive a user request including a user identifier for content from a user device; identify an experiment key for the user request based at least in part on the user identifier, the experiment key associated with an experimental version of the content; and transmit an experiment fetch request including the experiment key to an edge cache to retrieve the experimental version of the content.

Abstract: Content providers may wish to display different versions of content to different users, which may require different versions of the content to be deliverable. The assignment of a particular version of the content to a particular user may also need to persist over time for that particular user. It may be desirable that this functionality occurs at an edge server of a content delivery network, rather than at an origin server. In some embodiments, the edge server may receive a user request including a user identifier for content from a user device; identify an experiment key for the user request based at least in part on the user identifier, the experiment key associated with an experimental version of the content; and transmit an experiment fetch request including the experiment key to an edge cache to retrieve the experimental version of the content.

Abstract: An injectable elastin-like recombinamer (ELR) hydrogel for use in a method of treating a mammal that has suffered a myocardial infarction to modulate the response of cardiac muscle damaged by the infarct is described. The hydrogel is injected into the cardiac muscle damaged by the infarct at least two days after the myocardial infarction, and results in clinically significant repair of cardiac muscle evidenced by at least one or more of reduced scarring, positive remodelling of the damaged muscle, restoring cardiac muscle function to a clinically significant extent after infarction an improvement in angiogenesis, or a decreased pro-inflammatory response in the infarct zone, and typically within 10, 20 or 30 days of administration.